Regulation of Bile Acid and Cholesterol Metabolism by PPARs

Bile acids are amphipathic molecules synthesized from cholesterol in the liver. Bile acid synthesis is a major pathway for hepatic cholesterol catabolism. Bile acid synthesis generates bile flow which is important for biliary secretion of free cholesterol, endogenous metabolites, and xenobiotics. Bile acids are biological detergents that facilitate intestinal absorption of lipids and fat-soluble vitamins. Recent studies suggest that bile acids are important metabolic regulators of lipid, glucose, and energy homeostasis. Agonists of peroxisome proliferator-activated receptors (PPARα, PPARγ, PPARδ) regulate lipoprotein metabolism, fatty acid oxidation, glucose homeostasis and inflammation, and therefore are used as anti-diabetic drugs for treatment of dyslipidemia and insulin insistence. Recent studies have shown that activation of PPARα alters bile acid synthesis, conjugation, and transport, and also cholesterol synthesis, absorption and reverse cholesterol transport. This review will focus on the roles of PPARs in the regulation of pathways in bile acid and cholesterol homeostasis, and the therapeutic implications of using PPAR agonists for the treatment of metabolic syndrome.

[1]  O. Barbier,et al.  Lipid-activated transcription factors control bile acid glucuronidation , 2009, Molecular and Cellular Biochemistry.

[2]  Xingguo Cheng,et al.  Critical role of PPAR-alpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake transporters in mouse livers. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  B. Staels,et al.  Intestine-specific regulation of PPARalpha gene transcription by liver X receptors. , 2008, Endocrinology.

[4]  Xian Wang,et al.  Peroxisome proliferator‐activated receptor‐δ induces insulin‐induced gene‐1 and suppresses hepatic lipogenesis in obese diabetic mice , 2008, Hepatology.

[5]  J. Inoue,et al.  PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine. , 2008, Biochemical and biophysical research communications.

[6]  William J Zuercher,et al.  Recent advances in liver X receptor biology and chemistry. , 2008, Current topics in medicinal chemistry.

[7]  S. Cotler,et al.  Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. , 2008, World journal of gastroenterology.

[8]  N. Ballatori,et al.  Ost-Ost is required for bile acid and conjugated steroid disposition in the intestine , kidney , and liver , 2008 .

[9]  W. Howard Effect of Torcetrapib on the Progression of Coronary Atherosclerosis , 2008 .

[10]  J. George,et al.  Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. , 2008, Molecular pharmaceutics.

[11]  J. Repa,et al.  Fenofibrate reduces intestinal cholesterol absorption via PPARα-dependent modulation of NPC1L1 expression in mouse Published, JLR Papers in Press, August 28, 2007. , 2007, Journal of Lipid Research.

[12]  J. Repa,et al.  Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. , 2007, Journal of lipid research.

[13]  B. Salman,et al.  Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study , 2007, BMC gastroenterology.

[14]  J. Plutzky,et al.  PPARα in atherosclerosis and inflammation , 2007 .

[15]  D. Grobbee,et al.  Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[16]  J. Jukema,et al.  Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression Published, JLR Papers in Press, May 24, 2007. , 2007, Journal of Lipid Research.

[17]  D. Grobbee,et al.  Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .

[18]  Jean-Claude Tardif,et al.  Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.

[19]  R. Tukey,et al.  Expression of the Human UGT1 Locus in Transgenic Mice by 4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic Acid (WY-14643) and Implications on Drug Metabolism through Peroxisome Proliferator-Activated Receptor α Activation , 2007, Drug Metabolism and Disposition.

[20]  K. Eder,et al.  Activation of PPARalpha lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2. , 2007, Biochemical pharmacology.

[21]  K. Eder,et al.  PPARγ Ligand Troglitazone Lowers Cholesterol Synthesis in HepG2 and Caco-2 Cells via a Reduced Concentration of Nuclear SREBP-2 , 2006, Experimental biology and medicine.

[22]  F. Gonzalez,et al.  Ligand-activated PPARβ efficiently represses the induction of LXR-dependent promoter activity through competition with RXR , 2006, Molecular and Cellular Endocrinology.

[23]  M. Hayden,et al.  Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. , 2006, Annual review of nutrition.

[24]  G. Lewis Determinants of plasma HDL concentrations and reverse cholesterol transport , 2006, Current opinion in cardiology.

[25]  Albert K Groen,et al.  Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. , 2006, The Journal of clinical investigation.

[26]  R. Evans,et al.  PPARδ: a dagger in the heart of the metabolic syndrome , 2006 .

[27]  P. Mann,et al.  Oral Toxicity Study of 2-Pentenenitrile in Rats with Reproductive Toxicity Screening Test , 2006, Drug and chemical toxicology.

[28]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[29]  A. Vercelli,et al.  Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. , 2005, World journal of gastroenterology.

[30]  Jonathan C. Cohen,et al.  ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile Published, JLR Papers in Press, June 1, 2005. DOI 10.1194/jlr.M500115-JLR200 , 2005, Journal of Lipid Research.

[31]  G. Gibbons,et al.  A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver. , 2005, The Biochemical journal.

[32]  P. Besnard,et al.  The gene encoding the human ileal bile acid-binding protein (I-BABP) is regulated by peroxisome proliferator-activated receptors. , 2005, Biochimica et biophysica acta.

[33]  M. Hayden,et al.  Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. , 2005, The Journal of clinical investigation.

[34]  Jonathan C. Cohen,et al.  Expression of ABCG5 and ABCG8 Is Required for Regulation of Biliary Cholesterol Secretion* , 2005, Journal of Biological Chemistry.

[35]  B. Staels,et al.  Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1 Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400400-JLR200 , 2005, Journal of Lipid Research.

[36]  B. Staels,et al.  Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1 Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400400-JLR200 , 2005, Journal of Lipid Research.

[37]  P. Dawson,et al.  The Heteromeric Organic Solute Transporter α-β, Ostα-Ostβ, Is an Ileal Basolateral Bile Acid Transporter* , 2005, Journal of Biological Chemistry.

[38]  Andrew J. Brown,et al.  Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARγ ligands , 2005 .

[39]  J. Kastelein,et al.  Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. , 2005, Journal of the American College of Cardiology.

[40]  G. Salen,et al.  Bile acid biosynthesis , 1974, The American Journal of Digestive Diseases.

[41]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .

[42]  A. Bookout,et al.  Prevention of cholesterol gallstone disease by FXR agonists in a mouse model , 2004, Nature Medicine.

[43]  L. Csiba,et al.  Transcriptional Regulation of Human CYP27 Integrates Retinoid, Peroxisome Proliferator-Activated Receptor, and Liver X Receptor Signaling in Macrophages , 2004, Molecular and Cellular Biology.

[44]  Heidi R. Kast-Woelbern,et al.  Rosiglitazone Induction of Insig-1 in White Adipose Tissue Reveals a Novel Interplay of Peroxisome Proliferator-activated Receptor γ and Sterol Regulatory Element-binding Protein in the Regulation of Adipogenesis* , 2004, Journal of Biological Chemistry.

[45]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[46]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.

[47]  Luquan Wang,et al.  Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .

[48]  B. Staels,et al.  Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice , 2004 .

[49]  G. Gibbons,et al.  Inhibition of cholesterol absorption associated with a PPARα-dependent increase in ABC binding cassette transporter A1 in mice Published, JLR Papers in Press, August 1, 2003. DOI 10.1194/jlr.M300042-JLR200 , 2003, Journal of Lipid Research.

[50]  G. Gibbons,et al.  Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. , 2003, Journal of lipid research.

[51]  J. Borensztajn,et al.  The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. , 2003, The Biochemical journal.

[52]  H. Sone,et al.  Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. , 2003, Molecular endocrinology.

[53]  R. Evans,et al.  Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity , 2003, Cell.

[54]  S. Grundy,et al.  Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. , 2003, The American journal of cardiology.

[55]  J. Boyer,et al.  Bile salt transporters: molecular characterization, function, and regulation. , 2003, Physiological reviews.

[56]  B. Staels,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. , 2003, The Biochemical journal.

[57]  B. Staels,et al.  Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. , 2003, Molecular endocrinology.

[58]  B. Staels,et al.  Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. , 2003, Gastroenterology.

[59]  Y. Chao,et al.  Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice* , 2002, The Journal of Biological Chemistry.

[60]  P. Shah Low-density lipoprotein lowering and atherosclerosis progression: does more mean less? , 2002, Circulation.

[61]  J. Goldstein,et al.  Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Jonathan C. Cohen,et al.  Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. , 2002, The Journal of clinical investigation.

[63]  M. Fried,et al.  Human Apical Sodium-dependent Bile Salt Transporter Gene (SLC10A2) Is Regulated by the Peroxisome Proliferator-activated Receptor α* , 2002, The Journal of Biological Chemistry.

[64]  R. Aebersold,et al.  Crucial Step in Cholesterol Homeostasis Sterols Promote Binding of SCAP to INSIG-1, a Membrane Protein that Facilitates Retention of SREBPs in ER , 2002, Cell.

[65]  Aldons J. Lusis,et al.  Identification of macrophage liver X receptors as inhibitors of atherosclerosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J. Chiang,et al.  Bile acid regulation of gene expression: roles of nuclear hormone receptors. , 2002, Endocrine reviews.

[67]  D. Crabb,et al.  Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. , 2002, Gastroenterology.

[68]  H. Hobbs,et al.  Regulation of ATP-binding Cassette Sterol Transporters ABCG5 and ABCG8 by the Liver X Receptors α and β* , 2002, The Journal of Biological Chemistry.

[69]  T. Willson,et al.  Synthetic LXR ligand inhibits the development of atherosclerosis in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  C. Glass,et al.  Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux , 2002, Molecular and Cellular Biology.

[71]  V. Athyros,et al.  Atorvastatin versus Four Statin–Fibrate Combinations in Patients with Familial Combined Hyperlipidaemia , 2002, Journal of cardiovascular risk.

[72]  H. Sone,et al.  Polyunsaturated Fatty Acids Suppress Sterol Regulatory Element-binding Protein 1c Promoter Activity by Inhibition of Liver X Receptor (LXR) Binding to LXR Response Elements* , 2002, The Journal of Biological Chemistry.

[73]  M. Matsuda,et al.  Small Heterodimer Partner, an Orphan Nuclear Receptor, Augments Peroxisome Proliferator-activated Receptor γ Transactivation* , 2002, The Journal of Biological Chemistry.

[74]  P. Meier,et al.  Bile salt transporters. , 2002, Annual review of physiology.

[75]  J. Després,et al.  Increasing high-density lipoprotein cholesterol: an update on fenofibrate. , 2001, The American journal of cardiology.

[76]  F. Gonzalez,et al.  Antagonism of the Actions of Peroxisome Proliferator-activated Receptor-α by Bile Acids* , 2001, The Journal of Biological Chemistry.

[77]  R. Walczak,et al.  Autoregulation of the Human Liver X Receptor α Promoter , 2001, Molecular and Cellular Biology.

[78]  B Staels,et al.  Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator–Activated Receptor-&agr;–Mediated Downregulation of Cholesterol 7&agr;-Hydroxylase and Sterol 27-Hydroxylase Expression , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[79]  Gaochao Zhou,et al.  27-Hydroxycholesterol Is an Endogenous Ligand for Liver X Receptor in Cholesterol-loaded Cells* , 2001, The Journal of Biological Chemistry.

[80]  Paul T. Tarr,et al.  Characterization of the Human ABCG1 Gene , 2001, The Journal of Biological Chemistry.

[81]  M. Seishima,et al.  Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine. , 2001, Journal of lipid research.

[82]  J. Capone,et al.  The short heterodimer partner receptor differentially modulates peroxisome proliferator-activated receptor α-mediated transcription from the peroxisome proliferator-response elements of the genes encoding the peroxisomal β-oxidation enzymes acyl-CoA oxidase and hydratase-dehydrogenase , 2001, Molecular and Cellular Endocrinology.

[83]  Hitoshi Shimano,et al.  Identification of Liver X Receptor-Retinoid X Receptor as an Activator of the Sterol Regulatory Element-Binding Protein 1c Gene Promoter , 2001, Molecular and Cellular Biology.

[84]  C. Semenkovich,et al.  PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. , 2001, The Journal of clinical investigation.

[85]  J. Auwerx,et al.  Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[86]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[87]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[88]  N. Grishin,et al.  Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. , 2000, Science.

[89]  T. Willson,et al.  Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation* , 2000, The Journal of Biological Chemistry.

[90]  Jean-Marc A. Lobaccaro,et al.  Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ , 2000 .

[91]  D. Mangelsdorf,et al.  Role of LXRs in control of lipogenesis. , 2000, Genes & development.

[92]  A. Soutar,et al.  The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. , 2000, The Biochemical journal.

[93]  P. Edwards,et al.  Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[94]  M. Hunt,et al.  The Peroxisome Proliferator-activated Receptor α (PPARα) Regulates Bile Acid Biosynthesis* , 2000, The Journal of Biological Chemistry.

[95]  N. Hagenbuch,et al.  Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full‐length isoform of the liver‐specific transporter‐1 (rlst‐1) in rat liver , 2000, FEBS letters.

[96]  B. Levy,et al.  Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. , 2000, Genomics.

[97]  C. Gabel,et al.  High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[98]  J. Chiang,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. , 2000, Journal of lipid research.

[99]  D. Crabb,et al.  Peroxisome proliferator‐activated receptor γ transcriptional regulation is involved in platelet‐derived growth factor–induced proliferation of human hepatic stellate cells , 2000 .

[100]  J. Chiang,et al.  Peroxisome proliferator-activated receptor a (PPAR a ) and agonist inhibit cholesterol 7 a -hydroxylase gene ( CYP7A1 ) transcription , 2000 .

[101]  A. Groen,et al.  Mechanisms of Biliary Lipid Secretion and Their Role in Lipid Homeostasis , 2000, Seminars in liver disease.

[102]  P. Meier,et al.  Hepatic Transport of Bile Salts , 2000, Seminars in liver disease.

[103]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[104]  H. Shimano,et al.  A Crucial Role of Sterol Regulatory Element-binding Protein-1 in the Regulation of Lipogenic Gene Expression by Polyunsaturated Fatty Acids* , 1999, The Journal of Biological Chemistry.

[105]  P. Shah,et al.  Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. , 1999, Biochemical and biophysical research communications.

[106]  M. Brown,et al.  A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[107]  O. Gotoh,et al.  Structure, evolution, and liver-specific expression of sterol 12alpha-hydroxylase P450 (CYP8B). , 1999, Journal of biochemistry.

[108]  H. Yawo,et al.  Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1* , 1999, The Journal of Biological Chemistry.

[109]  D. Lütjohann,et al.  Removal of cholesterol from extrahepatic sources by oxidative mechanisms. , 1999, Current opinion in lipidology.

[110]  S. Kliewer,et al.  Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[111]  V. Laudet,et al.  The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates* , 1998, The Journal of Biological Chemistry.

[112]  M. Waterman,et al.  Activities of Recombinant Human Cytochrome P450c27 (CYP27) Which Produce Intermediates of Alternative Bile Acid Biosynthetic Pathways* , 1998, The Journal of Biological Chemistry.

[113]  R. Hammer,et al.  Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα , 1998, Cell.

[114]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[115]  R. McPherson,et al.  Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. , 1998, The American journal of cardiology.

[116]  Stacey,et al.  Structural requirements of ligands for the oxysterol liver X receptors LXR a and LXR b , 1998 .

[117]  P. Meier,et al.  Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver , 1997, Hepatology.

[118]  J. Auwerx,et al.  Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice* , 1997, The Journal of Biological Chemistry.

[119]  P. Meier,et al.  Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[120]  N. Freimer,et al.  Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. , 1997, American journal of human genetics.

[121]  P. Dawson,et al.  Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). , 1997, The Journal of clinical investigation.

[122]  Timothy M. Willson,et al.  Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway* , 1997, The Journal of Biological Chemistry.

[123]  P. Denéfle,et al.  Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. , 1996, Circulation.

[124]  J. Auwerx,et al.  Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. , 1996, The Journal of clinical investigation.

[125]  J. Capone,et al.  The Orphan Nuclear Hormone Receptor LXR Interacts with the Peroxisome Proliferator-activated Receptor and Inhibits Peroxisome Proliferator Signaling (*) , 1996, The Journal of Biological Chemistry.

[126]  D. Lütjohann,et al.  Novel pathways for elimination of cholesterol by extrahepatic formation of side-chain oxidized oxysterols. , 1996, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[127]  P. Meier Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. , 1995, The American journal of physiology.

[128]  N. Abate,et al.  Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[129]  V. Ling,et al.  Identification of a sister gene to P-glycoprotein. , 1995, Cancer research.

[130]  K. Einarsson,et al.  Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7α‐hydroxylase , 1995, Hepatology.

[131]  A. Hofmann Bile acids as drugs: principles, mechanisms of action and formulations. , 1995, The Italian journal of gastroenterology.

[132]  P. Dawson,et al.  Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. , 1995, The Journal of clinical investigation.

[133]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[134]  E. Everett,et al.  Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[135]  P. Meier,et al.  Expression cloning of a rat liver Na(+)-independent organic anion transporter. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[136]  P. Borst,et al.  Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease , 1993, Cell.

[137]  I. Björkhem,et al.  Mechanism of degradation of the steroid side chain in the formation of bile acids. , 1992, Journal of lipid research.

[138]  K. Anderson,et al.  Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. , 1992, Journal of the American College of Cardiology.

[139]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[140]  J. Auwerx,et al.  Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[141]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[142]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[143]  J. Sjövall,et al.  Potential bile acid precursors in plasma--possible indicators of biosynthetic pathways to cholic and chenodeoxycholic acids in man. , 1990, Journal of steroid biochemistry.

[144]  V. Fuster,et al.  Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.

[145]  J. Sjövall,et al.  Occurrence of 3 beta-hydroxy-5-cholestenoic acid, 3 beta,7 alpha-dihydroxy-5-cholestenoic acid, and 7 alpha-hydroxy-3-oxo-4-cholestenoic acid as normal constituents in human blood. , 1988, Journal of lipid research.

[146]  M. Axelson,et al.  Occurrence of 3~-hydroxy-5-cholestenoic acid, 3@ ,7a-di hydroxy-5-cholestenoic acid, and 7a- hyd roxy-3-oxo-4-c holestenoic acid as nor mal constituents in human blood , 1988 .

[147]  K. von Bergmann,et al.  Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. , 1988, Journal of lipid research.

[148]  A. Gnasso,et al.  Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects. , 1985, Metabolism: clinical and experimental.

[149]  S. Grundy,et al.  Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. , 1984, JAMA.

[150]  U. Goldbourt,et al.  ASSOCIATIONS OF SERUM HIGH DENSITY LIPOPROTEIN AND TOTAL CHOLESTEROL WITH TOTAL, CARDIOVASCULAR, AND CANCER MORTALITY IN A 7-YEAR PROSPECTIVE STUDY OF 10 000 MEN , 1981, The Lancet.

[151]  J. Boyer New concepts of mechanisms of hepatocyte bile formation. , 1980, Physiological reviews.

[152]  J. Berndt,et al.  Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liver. , 1978, Atherosclerosis.

[153]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[154]  K. Mitropoulos,et al.  Cholesterol 7 alpha-hydroxylase. , 1977, Journal of lipid research.

[155]  E. Mosbach Regulation of bile acid synthesis. , 1974, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin.

[156]  S. Grundy,et al.  Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. , 1972, Journal of lipid research.

[157]  A. Soutar,et al.  The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. , 2000, The Biochemical journal.